Senate Passes CHRONIC Care Act of 2017

The U.S. Senate passed the Creating High-Quality Results and Outcomes Necessary to Improve Chronic(CHRONIC) Care Act of 2017, which aims to improve care for seniors with chronic conditions.

FDA Approves First Subcutaneous Therapy to Treat HAE

The U.S. Food and Drug Administration has approved CSL Behring’s Haegarda (C1 esterase inhibitor subcutaneous [human]), the first and only subcutaneous therapy indicated for routine prophylaxis to prevent hereditary angioedema attacks in adolescent and adult patients.

CSL Behring ’s Privigen Now Approved to Treat CIDP

The U.S. Food and Drug Administration (FDA) has approved Privigen (immune globulin intravenous [human] 10% liquid) to treat adults with chronic inflammatory demyelinating polyneuropathy (CIDP) to improve neuromuscular disability.

CSL Behring Awards LEAD Grants to Support Patient Rights

CSL Behring has awarded three U.S. bleeding disorder patient organizations Local Empowerment for Advocacy Development (LEAD) grants to help them ensure patients’ voices continue to be heard in their state capitals on legislative and public policy issues.

Clinical Trial of Universal Flu Vaccine Is a Success

Scientists at the National Institutes of Health, Frederick National Laboratory for Cancer Research and the University of Melbourne in Australia tested a new universal flu vaccine that produced good immunity against several different strains of influenza viruses.